(Z)-Ethyl 3-cyano-2-hydroxyacrylate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Z)-Ethyl 3-cyano-2-hydroxyacrylate
• 英文别名: ethyl (Z)-3-cyano-2-hydroxyprop-2-enoate
• 化学式: C₆H₇NO₃
• 分子量: 141.12
• InChiKey: XHJJYDFHJMQSDB-HYXAFXHYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  70.3
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• 5-Membered heterocyclic compound
  申请人：Nishida Haruyuki

  公开号：US20090156642A1

  公开（公告）日：2009-06-18

  The present invention provides 5-membered heterocycle compounds represented by the following general formula (I): The present compounds have a superior acid secretion inhibitory effect, and shows an antiulcer activity and the like.

  本发明提供了以下通式(I)表示的5元杂环化合物： 本化合物具有优异的抑制胃酸分泌效果，并显示出抗溃疡活性等。
• [EN] ALKYNYL ALCOHOLS AND METHODS OF USE<br/>[FR] ALCOOLS D'ALCYNYLE ET PROCÉDÉS D'UTILISATION CORRESPONDANTS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015025025A1

  公开（公告）日：2015-02-26

  The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over- activation of NF-kB signaling is observed.

  这项发明涉及以下式的化合物（0）：其中Q，A1-A8，R4和R5分别具有如本文所述的含义。式（0）的化合物及其药物组成物在治疗观察到NF-kB信号通路的不良或过度活化的疾病和紊乱中是有用的。
• Pyrazolopyrimidines, a process for their preparation and their use as medicine
  申请人：Danysz Wojciech

  公开号：US20080032998A1

  公开（公告）日：2008-02-07

  Substituted pyrazolopyrimidine derivatives of formula (I) wherein R 1 represents chloro or bromo; R 2 , R 3 , R 4 , R 5 , R 6 and R 7 independently represent e.g. hydrogen or C 1-6 -alkyl; R 8 represents a radical R 9 or a radical R 10 , whereby one of the two radicals R 8 represents R 9 and the other radical R 8 represents Ret; R 9 represents e.g. a phenyl or thiophene group, and R 10 represents e.g. hydrogen or methyl; are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.

  取代吡唑并嘧啶衍生物的公式(I) 其中 R1代表氯或溴； R2、R3、R4、R5、R6和R7独立代表例如氢或C1-6-烷基； R8代表R9的基团或R10的基团，其中两个R8基团之一代表R9，另一个R8基团代表Ret；R9代表例如苯基或噻吩基团，R10代表例如氢或甲基； 是有效的mGluR5调节剂，可用于预防急性和慢性神经障碍。
• [EN] MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS<br/>[FR] MACROCYCLES À GROUPES HÉTÉROCYCLIQUES P2' SERVANT D'INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015116886A1

  公开（公告）日：2015-08-06

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽酶的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES
  申请人：ChemoCentryx, Inc.

  公开号：US20130225580A1

  公开（公告）日：2013-08-29

  Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.

  提供的化合物作为CCR(9)受体的有效拮抗剂。动物实验表明，这些化合物对于治疗CCR(9)引起的炎症非常有效。这些化合物通常是芳基磺酰胺衍生物，可用于制药组合物、治疗CCR(9)介导的疾病的方法，以及作为鉴定CCR(9)拮抗剂的检测中的对照物。